PHG - Koninklijke Philips N.V.

NYSE - NYSE Delayed Price. Currency in USD
47.17
+0.59 (+1.27%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close46.58
Open47.19
Bid44.01 x 800
Ask47.24 x 1300
Day's Range47.11 - 47.83
52 Week Range30.50 - 50.78
Volume721,848
Avg. Volume1,362,900
Market Cap42.125B
Beta (5Y Monthly)1.09
PE Ratio (TTM)29.85
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateMay 05, 2020
1y Target EstN/A
All
News
Press Releases
  • GlobeNewswire

    FDA issues Emergency Use Authorization for Philips’ new acute care patient monitoring solutions for hospital-based remote monitoring

    June 2, 2020 Philips’ IntelliVue Patient Monitors MX750/MX850, IntelliVue 4-Slot Module Rack FMX-4 and IntelliVue Active Displays AD75/AD85 receive FDA Emergency Use.

  • Royal Philips Ranked Among Top 10 Largest Public Healthcare Companies in Forbes Annual Global 2000 Listing
    Business Wire

    Royal Philips Ranked Among Top 10 Largest Public Healthcare Companies in Forbes Annual Global 2000 Listing

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the company once again has earned a place on the Forbes "Global 2000: The World’s Largest Public Companies" list, moving up 46 spots from 2019. In its new 2020 position, the company now also ranks as one of the top ten global public healthcare companies. The annual list, which has been released for the past 18 years, features a ranking of the biggest, most powerful and most valuable companies in the world. Philips ranked 385 out of the 2,000 publicly traded companies on the full list.

  • GlobeNewswire

    Philips Foundation publishes its 2019 Annual Report

    Philips Foundation, with its mission to provide access to quality healthcare for disadvantaged communities through innovation, today announced publication of its 2019 Annual Report. The report outlines a year of substantial progress in providing access to quality healthcare for disadvantaged communities, capturing many of the activities that aim to achieve lasting change in local healthcare systems.

  • Masimo and Philips Licensing Agreement Brings Masimo NomoLine® Capnography and O3® Regional Oximetry to Select Philips Patient Monitors
    Business Wire

    Masimo and Philips Licensing Agreement Brings Masimo NomoLine® Capnography and O3® Regional Oximetry to Select Philips Patient Monitors

    Philips is integrating additional Masimo monitoring technologies into select Philips multi-parameter patient monitors.

  • GlobeNewswire

    Philips launches next generation wearable biosensor for early patient deterioration detection, including clinical surveillance for COVID-19

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its wearable biosensor (Philips Biosensor BX100) to help manage confirmed and suspected COVID-19 patients in the hospital. The next generation wireless wearable biosensor enhances clinical surveillance in the Philips patient deterioration detection solution to help clinicians detect risk so they can intervene earlier and help improve care for patients in lower acuity care areas.

  • GlobeNewswire

    Philips launches HealthSuite Clinical Trial Accelerator to help life science organizations run more flexible, patient-centric clinical trials

    May 19, 2020 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Clinical Trial Accelerator on.

  • GlobeNewswire

    Philips receives FDA clearance for the use of its ultrasound portfolio to manage COVID-19-related lung and cardiac complications

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market a wide range of its ultrasound solutions for the management of COVID-19-related lung and cardiac complications. Handheld and portable ultrasound solutions in particular have become valuable tools for clinicians treating COVID-19 patients due to their imaging capabilities, portability and ease of disinfection. As a result of this regulatory clearance, which is an industry first, Philips can provide detailed, practical guidance to support clinicians using its systems and software for patients affected by COVID-19.

  • GlobeNewswire

    Philips to convene Extraordinary General Meeting of Shareholders

    Royal Philips (NYSE: PHG, AEX: PHIA) today announced that it will convene an Extraordinary General Meeting of Shareholders (EGM) and publish the agenda with explanatory note shortly. The sole purpose of the EGM is submit to Philips’ shareholders the revised proposal, as announced on April 20, 2020, to declare a distribution of EUR 0.85 per common share against the net income for 2019, in shares only. To protect the health and safety of all participants in connection with COVID-19 and considering the temporary legislative measures from the Dutch government, shareholders are invited to submit their voting instructions and follow the meeting via the live webcast only, which will be available on Philips’ website.

  • GlobeNewswire

    Philips first of its kind ultrasound solution for pediatric assessment provides a gentler approach to imaging children

    May 6, 2020  Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the ultimate ultrasound solution.

  • GlobeNewswire

    Philips Annual General Meeting of Shareholders approves all proposals

    April 30, 2020  Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) announced that today’s Annual General Meeting of Shareholders (2020 AGM) has approved the.

  • GlobeNewswire

    FDA lifts injunction on manufacture and distribution of Philips’ defibrillators in the US

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced today that its Emergency Care and Resuscitation (ECR) business is resuming manufacturing and shipping of external defibrillators for the US, following notification from the US Food and Drug Administration (FDA) that the injunction prohibiting those activities has been lifted. This business has been operating under a consent decree with the FDA since November 2017. Under the terms of the consent decree, Philips was required to suspend manufacture and distribution of its defibrillators from specific Philips facilities in the U.S., pending FDA certification via inspection of the facilities’ compliance with Quality System Regulation.

  • ACCESSWIRE

    Koninklijke Philips NV to Host Earnings Call

    WNEW YORK, NY / ACCESSWIRE / April 20, 2020 / Koninklijke Philips NV (NYSE:PHG) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on April 20, 2020 at 10:00 ...

  • GlobeNewswire

    Philips delivers Q1 sales of EUR 4.2 billion, with 2% comparable sales decrease; income from continuing operations amounted to EUR 42 million and Adjusted EBITA margin was 5.9%

    At Philips, we are focused on our triple duty of care: meeting critical customer needs, safeguarding the health and safety of our employees, and ensuring business continuity. There was increased demand for our professional healthcare products and solutions, with comparable sales and order intake growth for the Connected Care and Diagnosis & Treatment businesses. This resulted in a 2% comparable sales decrease and an Adjusted EBITA margin of 5.9% for the Group.

  • GlobeNewswire

    Philips teams with University of Kentucky's UK HealthCare to power state’s only eICU Clinical Command Center

    April 15, 2020 Academic medical center leverages Philips tele-ICU technology to enhance clinician experience and help improve outcomes for ICU patients in Kentucky.

  • GlobeNewswire

    Philips details plans to increase its hospital ventilator production to 4,000 units/week by Q3 2020, and introduces its new Philips Respironics E30 ventilator with an immediate production of 15,000 units/week

    Philips continues to work with its global suppliers to ensure a sufficient and uninterrupted supply of components. Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today provided an update on its plans to double the production of its hospital ventilators by May 2020 and achieve a four-fold increase by the third quarter of 2020.

  • GlobeNewswire

    KLM and Philips to set up a special freight airlift from Amsterdam to China

    With the current loss of around 90% of all flights between Europe and Asia, there is a major shortage of freight capacity. At the same time, and precisely because of the crisis surrounding COVID-19, there is a huge requirement to transport medical equipment and other supplies quickly between the US, Europe and China. KLM has now joined forces with Royal Philips (NYSE: PHG; AEX: PHIA) and the Dutch government to create a temporary special cargo airlift between the Netherlands and China.

  • GlobeNewswire

    Philips and the U.S. government collaborate in ventilator production ramp up to combat COVID-19 pandemic

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that the U.S. Government and Philips agreed to team up to increase the production of hospital ventilators in its manufacturing sites in the U.S. Philips plans to double the production by May 2020  and achieve a four-fold increase by the third quarter of 2020 for supply to the U.S. and global markets. Such ventilators are critical for the treatment of patients with the new coronavirus disease (COVID-19). Philips will invest several tens of millions in its ventilator manufacturing sites in the U.S.

  • GlobeNewswire

    FDA's enforcement discretion allowing to expand remote use of Philips IntelliSite Pathology Solution during COVID-19 emergency

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced that the FDA has granted a waiver for the use of readily available consumer monitors at home with the Philips IntelliSite Pathology Solution [1]. Pathologists, who may not be able to work on-site due to the current COVID-19 emergency, can start working from home to review pathological cases and so prevent any delay in critical patient care.

  • GlobeNewswire

    Philips enables hospitals and GPs to remotely screen and monitor patients with COVID-19

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it can help general practitioners and healthcare institutions manage the increased patient flows resulting from the COVID-19 outbreak through a dedicated and scalable telehealth solution that facilitates the use of online screening, follow-up questionnaires and monitoring, and external call center collaborations. It aims to prevent unnecessary visits to general practitioners and hospitals and the remote monitoring of the vast majority of COVID-19 patients that are in quarantine at home.

  • GlobeNewswire

    Philips to postpone its Capital Markets Day to the fourth quarter of 2020

    March 31, 2020 Amsterdam, the Netherlands – In connection with the coronavirus disease (COVID-19) outbreak and related precautionary measures, Royal Philips (NYSE:.

  • GlobeNewswire

    Philips successfully prices offering of Notes for EUR 1 billion

    Koninklijke Philips N.V. (“Royal Philips”) (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its issue of EUR 500 million fixed rate notes due 2025 and EUR 500 million fixed rate notes due 2030 (together the “Notes”). The net proceeds of the offering are intended for general company purposes and sustainable innovation expenditures as defined in the ESG framework available on the debt section of Philips Investor Relations website, and will further enhance the company’s liquidity position in view of the possible continued impact of the COVID-19 pandemic on financial markets in 2020. The issue price for the notes due 2025 is 99.550% with a Coupon of 1.375%, resulting in a yield of 1.469%.

  • GlobeNewswire

    Children’s Hospital of Georgia uses Philips’ automated early detection and warning solution to improve pediatric patient deterioration response

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that Children’s Hospital of Georgia has adopted Philips’ automated early detection and warning solution (IntelliVue GuardianSoftware) for pediatrics. This scalable solution, which could be comprised of a combination of patient monitoring, telehealth, predictive analytics software and services, enables quick identification of signals of clinical patient deterioration and triggers a warning notification to the hospital staff allowing faster response times.

  • GlobeNewswire

    Philips provides update on EUR 1.5 billion share repurchase program

    Royal Philips (NYSE: PHG, AEX: PHIA) today provides an update on its EUR 1.5 billion share buyback program for capital reduction purposes, that was announced on January 29, 2019. As of today, 50.3% of the program has been completed through repurchases by an intermediary to allow for purchases in the open market during both open and closed periods. The remainder of the program will be executed through one or more individual forward transactions, to be entered into in the course of 2020, with expected settlement dates in the second half of 2021.

  • GlobeNewswire

    Philips ramps up production of critical health technology products in response to COVID-19 pandemic

    Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it is increasing the production of certain critical care products and solutions to help diagnose and treat patients with the new coronavirus disease (COVID-19). Other Philips products and solutions to help address the preparedness, response and recovery needs of COVID-19 include a range of diagnostic imaging systems (CT, mobile diagnostic X-ray, and ultrasound) to help diagnose and assess respiratory conditions, as well as hospital telehealth solutions to centrally monitor and manage patients in the intensive care unit (Philips eICU program), and telehealth solutions to connect caregivers and patients at home. For example, Philips is ramping up the production of hospital ventilators and plans to double production within the next eight weeks and achieve a four-fold increase by the third quarter of 2020.

  • GlobeNewswire

    Statement of Philips CEO Frans van Houten on the COVID-19 outbreak

    March 18, 2020 Amsterdam, the Netherlands – Frans van Houten, CEO of Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today provided an.